{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-005595","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2023-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.604168+00:00","generated_at":"2026-06-10T22:51:55.736747+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corvus confirms soquelitinib Phase 3 trial for PTCL; initiation Q1 2024","bullets":["FDA End-of-Phase meeting completed; trial design confirmed: 150 patients, 1:1 randomization, primary endpoint PFS.","Enrollment of relapsed PTCL patients with ≤3 prior therapies; initiation expected in Q1 2024.","Company to host conference call on Sept 7, 2023 to discuss trial plan and business updates.","Soquelitinib is a selective ITK inhibitor; potential in hematologic cancers, solid tumors, autoimmune diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-005595","json":"https://secwatch.observer/filing/0001171843-23-005595.json","markdown":"https://secwatch.observer/filing/0001171843-23-005595.md","text":"https://secwatch.observer/filing/0001171843-23-005595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184323005595/0001171843-23-005595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184323005595/f8k_090623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:51:55.736747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}